GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » COGS-to-Revenue

Sophia Genetics (Sophia Genetics) COGS-to-Revenue : 0.34 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics COGS-to-Revenue?

Sophia Genetics's Cost of Goods Sold for the three months ended in Mar. 2024 was $5.37 Mil. Its Revenue for the three months ended in Mar. 2024 was $15.78 Mil.

Sophia Genetics's COGS to Revenue for the three months ended in Mar. 2024 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sophia Genetics's Gross Margin % for the three months ended in Mar. 2024 was 65.94%.


Sophia Genetics COGS-to-Revenue Historical Data

The historical data trend for Sophia Genetics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics COGS-to-Revenue Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 0.30 0.38 0.38 0.34 0.31

Sophia Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.33 0.31 0.30 0.34

Sophia Genetics COGS-to-Revenue Calculation

Sophia Genetics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=19.458 / 62.371
=0.31

Sophia Genetics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=5.374 / 15.779
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sophia Genetics  (NAS:SOPH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sophia Genetics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 5.374 / 15.779
=65.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Sophia Genetics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophia Genetics (Sophia Genetics) Business Description

Traded in Other Exchanges
Address
Rue du Centre 172, Saint-Sulpice, CHE, CH-1025
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.